83(b) Election in San Diego Biotech

If you work in San Diego biotech whether as a founder, early employee, or senior operator, I’m going to take a wild guess that your compensation includes Restricted Stock Awards (RSAs). And if that’s the case, one of the most important financial decisions you’ll ever make might come down to a single, time-sensitive filing: the 83(b) election.

For high-net-worth (HNW) and ultra-high-net-worth (UHNW) individuals, the implications of filing a 83(b) aren’t just tax efficiency, they’re wealth architecture.

What Is an 83(b) Election? (And Why It Exists)

An 83(b) election allows you to accelerate the taxation of restricted stock to the time of grant, rather than waiting until the shares vest.

In practical terms:

• Without 83(b): You pay ordinary income tax as your shares vest, based on their fair market value at that time
• With 83(b): You pay tax upfront, when the shares are typically worth very little

From that point forward, any appreciation is taxed at capital gains rates, not ordinary income.

Let’s take this out of financial advisor mode and into a digestible example

Earlier this year you join a biotech company in La Jolla at formation and receive RSAs at $0.001 per share. Fast forward to years later and after successful clinical data, the company is now valued at $20 per share.

As you can see, a simple filing could represent millions in tax savings.

Who Should Seriously Consider an 83(b) election?

Timing is Everything: You have 30 days!

One of the most critical aspects of a 83(b) election is that you get 30 days from the date of the grant to file. No extensions. No second chances. No retroactive fixes. If you miss the window, the opportunity is gone. 

You may hear that “filing a 83(b) is a no-brainer.” While that may be true in Silicon Valley, it’s not always the case in San Diego Biotech. I say this not to scare you but to know how important it is to work with someone who is well-versed in RSAs and biotech. The reason being; not all biotech companies survive. If you file a 83(b), you’re paying taxes upfront. So if the company fails or your shares never vest, the tax you paid is not recoverable. Filing form 83(b) should never be treated as an automatic strategy in biotech. 

From a fiduciary, who is legally and ethically required to act in the best interest of my clients, I believe the best outcomes from financial wealth in biotech start with a properly designed system that works in your best interest. 

If this sounds like a familiar situation, give the advisors at Your Dedicated Fiduciary a call. We’d be happy to look over your unique financial plan to find optimal strategies personalized to you.

Disclosures:

Your Dedicated Fiduciary® does not provide legal or tax advice. You should consult a legal or tax professional regarding your individual situation. Diversification does not assure a profit or protect against loss in declining markets, and diversification cannot guarantee that any objective or goal will be achieved. Roth conversions involve transferring funds from a pre-tax retirement account to a Roth account, triggering current income taxes on the converted amount in exchange for potential tax-free growth and withdrawals later.